Contact this trialFirst, we need to learn more about you.
ALK Inhibitor
Lorlatinib + Ramucirumab for Lung Cancer
Recruiting1 awardPhase 1 & 2
New York, New York
This trial will test the safety of a combination of drugs to treat metastatic ALK-rearranged NSCLC. Researchers will find the dose that causes few side effects, then test it in future participants to see if it works. They'll also look for genes associated with response.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service